Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

David Wyles; Ola Weiland; Betty Yao; Frank Weilert; Jean Francois Dufour; Stuart C. Gordon; Albrecht Stoehr; Ashley Brown; Stefan Mauss; Zhenzhen Zhang; Tami Pilot-Matias; Lino Rodrigues; Federico J. Mensa; Fred Poordad

doi:10.1016/j.jhep.2019.01.031

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

David Wyles, Ola Weiland, Betty Yao, Frank Weilert, Jean Francois Dufour, Stuart C. Gordon, Albrecht Stoehr, Ashley Brown, Stefan Mauss, Zhenzhen Zhang, Tami Pilot-Matias, Lino Rodrigues, Federico J. Mensa, Fred Poordad

UT Health San Antonio Transplant Center

Research output: Contribution to journal › Letter › peer-review

52 Scopus citations

Original language	English (US)
Pages (from-to)	1019-1023
Number of pages	5
Journal	Journal of Hepatology
Volume	70
Issue number	5
DOIs	https://doi.org/10.1016/j.jhep.2019.01.031
State	Published - May 2019

Keywords

G/P
HCV
RAS
Resistance
Retreatment

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.jhep.2019.01.031

Cite this

Wyles, D., Weiland, O., Yao, B., Weilert, F., Dufour, J. F., Gordon, S. C., Stoehr, A., Brown, A., Mauss, S., Zhang, Z., Pilot-Matias, T., Rodrigues, L., Mensa, F. J., & Poordad, F. (2019). Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. Journal of Hepatology, 70(5), 1019-1023. https://doi.org/10.1016/j.jhep.2019.01.031

@article{69c7d0973b904cc18e1f49d8296ea67d,

title = "Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection",

keywords = "G/P, HCV, RAS, Resistance, Retreatment",

author = "David Wyles and Ola Weiland and Betty Yao and Frank Weilert and Dufour, {Jean Francois} and Gordon, {Stuart C.} and Albrecht Stoehr and Ashley Brown and Stefan Mauss and Zhenzhen Zhang and Tami Pilot-Matias and Lino Rodrigues and Mensa, {Federico J.} and Fred Poordad",

note = "Funding Information: We thank the patients, trial investigators and coordinators who made this study possible, and AbbVie colleague Dr. Roger Trinh, MD for his contributions to study design and data analysis. Glecaprevir was identified by AbbVie and Enanta. Medical writing was provided by Zo{\"e} Hunter, PhD, of AbbVie, and funded by AbbVie. Funding Information: AbbVie sponsored the study, contributed to its design, participated in the collection, analysis and interpretation of the data, and in the writing, reviewing, and approval of the manuscript. All authors had access to relevant data. D Wyles: Consultant: AbbVie, Gilead and Merck; Research funds: AbbVie, Gilead and Merck. O Weiland: Speaker/Consultant: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and MSD/Merck. F Weilert: Study investigator: AbbVie. J-F Dufour: Advisory committees: AbbVie, Bayer, Bristol-Myers Squibb, Genfit, Gilead Science, Intercept, Merck, and Novartis; Unrestricted research grant: Bayer. S Gordon: Consultant: AbbVie, CVS Caremark, Gilead, and Merck; Grant Support: AbbVie, Gilead, Intercept, and Merck. A Stoehr: Speaker: AbbVie, Gilead, Janssen, and MSD; Advisor: AbbVie and ViiV. A Brown: Advisor/speaker/Research grants: Abbvie, Bristol-Meyers Squibb, Janssen, Gilead, and MSD. S Mauss: Speaker: AbbVie, Gilead, Janssen and MSD; Advisor: AbbVie, Gilead and MSD. F Poordad: Grant/research support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept Pharmaceuticals, Merck; Speaker: Abbvie, Bristol-Myers Squibb, Gilead, Intercept Pharmaceuticals, Merck, Salix; Consultant/advisor: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck. B Yao, Z Zhang, L Rodrigues Jr, FJ Mensa and T Pilot-Matias: employees of AbbVie and may hold stock or stock options. Funding Information: AbbVie sponsored the study (NCT02939989). We thank the patients, trial investigators and coordinators who made this study possible, and AbbVie colleague Dr. Roger Trinh, MD for his contributions to study design and data analysis. Glecaprevir was identified by AbbVie and Enanta. Medical writing was provided by Zo{\"e} Hunter, PhD, of AbbVie, and funded by AbbVie. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g. protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.",

year = "2019",

month = may,

doi = "10.1016/j.jhep.2019.01.031",

language = "English (US)",

volume = "70",

pages = "1019--1023",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

AU - Wyles, David

AU - Weiland, Ola

AU - Yao, Betty

AU - Weilert, Frank

AU - Dufour, Jean Francois

AU - Gordon, Stuart C.

AU - Stoehr, Albrecht

AU - Brown, Ashley

AU - Mauss, Stefan

AU - Zhang, Zhenzhen

AU - Pilot-Matias, Tami

AU - Rodrigues, Lino

AU - Mensa, Federico J.

AU - Poordad, Fred

N1 - Funding Information: We thank the patients, trial investigators and coordinators who made this study possible, and AbbVie colleague Dr. Roger Trinh, MD for his contributions to study design and data analysis. Glecaprevir was identified by AbbVie and Enanta. Medical writing was provided by Zoë Hunter, PhD, of AbbVie, and funded by AbbVie. Funding Information: AbbVie sponsored the study, contributed to its design, participated in the collection, analysis and interpretation of the data, and in the writing, reviewing, and approval of the manuscript. All authors had access to relevant data. D Wyles: Consultant: AbbVie, Gilead and Merck; Research funds: AbbVie, Gilead and Merck. O Weiland: Speaker/Consultant: AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and MSD/Merck. F Weilert: Study investigator: AbbVie. J-F Dufour: Advisory committees: AbbVie, Bayer, Bristol-Myers Squibb, Genfit, Gilead Science, Intercept, Merck, and Novartis; Unrestricted research grant: Bayer. S Gordon: Consultant: AbbVie, CVS Caremark, Gilead, and Merck; Grant Support: AbbVie, Gilead, Intercept, and Merck. A Stoehr: Speaker: AbbVie, Gilead, Janssen, and MSD; Advisor: AbbVie and ViiV. A Brown: Advisor/speaker/Research grants: Abbvie, Bristol-Meyers Squibb, Janssen, Gilead, and MSD. S Mauss: Speaker: AbbVie, Gilead, Janssen and MSD; Advisor: AbbVie, Gilead and MSD. F Poordad: Grant/research support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept Pharmaceuticals, Merck; Speaker: Abbvie, Bristol-Myers Squibb, Gilead, Intercept Pharmaceuticals, Merck, Salix; Consultant/advisor: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck. B Yao, Z Zhang, L Rodrigues Jr, FJ Mensa and T Pilot-Matias: employees of AbbVie and may hold stock or stock options. Funding Information: AbbVie sponsored the study (NCT02939989). We thank the patients, trial investigators and coordinators who made this study possible, and AbbVie colleague Dr. Roger Trinh, MD for his contributions to study design and data analysis. Glecaprevir was identified by AbbVie and Enanta. Medical writing was provided by Zoë Hunter, PhD, of AbbVie, and funded by AbbVie. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g. protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.

PY - 2019/5

Y1 - 2019/5

KW - G/P

KW - HCV

KW - RAS

KW - Resistance

KW - Retreatment

UR - http://www.scopus.com/inward/record.url?scp=85063105293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063105293&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2019.01.031

DO - 10.1016/j.jhep.2019.01.031

M3 - Letter

C2 - 30857780

AN - SCOPUS:85063105293

SN - 0168-8278

VL - 70

SP - 1019

EP - 1023

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 5

ER -

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this